Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumours (MK-7902-005/E7080-G000-224/LEAP-005)

Trial Centre Location Province Status
BC Cancer Agency - Abbotsford Centre Abbotsford British Columbia Closed
CancerCare Manitoba Winnipeg Manitoba Closed
Hamilton Health Sciences Hamilton Ontario Closed
Princess Margaret Cancer Centre Toronto Ontario Closed
Sunnybrook Health Sciences Centre Toronto Ontario Closed
CHU de Québec - Université Laval - L'Hôtel-Dieu de Québec Quebec Quebec Closed
CHUM - Nouveau Centre Hospitalier Universitaire de Montréal Montreal Quebec Closed

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society